Global Idiopathic
Thrombocytopenic Purpura (ITP) Therapeutics Market is expected to
reach USD 566.37 million by 2020, according to a new study by Grand View
Research, Inc. Introduction of new drugs especially pertaining to TPO-RA and
IVIG classes is expected to serve this market as a high impact rendering
driver. Presence of favorable government regulations such as the Orphan Drug
Act in the U.S. aimed at encouraging new product development is expected to
have a positive impact on the market. Most notable trend observed in this
market is an increase in demand for combination therapies involving two or more
drugs. Clinical evidences suggest that some combination therapies prove to be
cost effective, exhibit higher efficacies and help curb side effects otherwise
associated with individual therapeutic classes.
Corticosteroids are the most frequently administered therapy
for idiopathic thrombocytopenic purpura (ITP). The global corticosteroids
market for ITP was valued at over USD 125.0 million in 2013. Corticosteroids
are considered as the first line of treatment in patients with ITP and
therefore, enjoy very high usage rates.
Request to Sample
of This Report @ http://www.grandviewresearch.com/industry-analysis/idiopathic-thrombocytopenic-purpura-itp-therapeutics
Further key findings from the study suggest:
- TPO-RA is the most lucrative segment of this market and is expected to witness a surge in demand owing to the potential commercialization of Avatrombopag in 2015. Moreover, the ability of this class to cater to splenectomized patients witnessing relapses attributes to such rapid growth.
- North America accounted for over 40% of the global ITP market revenue in 2013, on account of high market penetration rates and favorable regulations. Presence of an extensive number of clinical trial studies related to combination therapy and new product development is also expected to drive regional growth during the forecast period.
- Europe was the second largest regional ITP therapeutics market in 2013 and is expected to maintain its position over the forecast period. High product usage rates and the presence of government initiatives granting special status to orphan drugs are some factors accounting for its large market share.
- Asia Pacific is expected to present high future growth potential over the next six years, owing to the presence of large untapped opportunities in the emerging markets of India and China. Presence of favorable government initiatives and sophisticated healthcare infrastructure in Japan and Australia are also expected to attribute to its market attractiveness.
- Key players of the ITP therapeutics market include GSK, Amgen Inc., Grifols Biologicals Inc., Eisai and F.Hoffman-La Roche.
To Get Sample Copy of Report visit
@ http://www.grandviewresearch.com/industry-analysis/idiopathic-thrombocytopenic-purpura-itp-therapeutics/request
About Grand View
Research
Grand View Research, Inc. is a U.S. based market research and
consulting company, registered in the State of California and headquartered in
San Francisco. The company provides syndicated research reports, customized
research reports, and consulting services. To help clients make informed
business decisions, the company offers market intelligence studies ensuring
relevant and fact-based research across a range of industries including
technology, chemicals, materials, healthcare and energy.
For More Information,
Visit Grand
View Research
Contact:
Sherry James
Corporate Sales Specialist, U.S.A.
Grand View Research, Inc.
United States
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email:
sales@grandviewresearch.com
No comments:
Post a Comment